In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER

Source Citation Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258-66. 29246950